Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1995-1-23
|
| pubmed:abstractText |
Dapsone is used widely in treating ocular cicatricial pemphigoid, leprosy, and dermatologic disorders. Hemolysis is a well-known complication of dapsone therapy. Rarely, neutropenia or agranulocytosis may occur, resulting in up to a 50% mortality rate. To the authors' knowledge, agranulocytosis has not been reported in patients treated with dapsone for ocular cicatricial pemphigoid.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0161-6420
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
101
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1805-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7800360-Aged,
pubmed-meshheading:7800360-Dapsone,
pubmed-meshheading:7800360-Eye Diseases,
pubmed-meshheading:7800360-Humans,
pubmed-meshheading:7800360-Male,
pubmed-meshheading:7800360-Neutropenia,
pubmed-meshheading:7800360-Pemphigoid, Benign Mucous Membrane,
pubmed-meshheading:7800360-Time Factors
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Dapsone-induced neutropenia in patients treated for ocular cicatricial pemphigoid.
|
| pubmed:affiliation |
New England Eye Center, Tufts University School of Medicine, Boston, MA 02111.
|
| pubmed:publicationType |
Journal Article,
Case Reports
|